Rakovina Therapeutics's latest marketcap:
As of 06/23/2025, Rakovina Therapeutics's market capitalization has reached $9.18 M. According to our data, Rakovina Therapeutics is the 40534th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 9.18 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -3,986,442.04 |
| Shares Out | 211.15 M |
| EPS (ttm) | -0.05 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/29/2025 |
Rakovina Therapeutics's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/23/2025 | C$9.18 M | -56.5% | 40534 |
| 12/31/2024 | C$26.69 M | 348.09% | 34657 |
| 12/29/2023 | C$5.96 M | -52.61% | 39944 |
| 12/29/2022 | C$12.57 M | -18.16% | 36213 |
| 12/31/2021 | C$15.36 M | 34847 |
Company Profile
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is a biopharmaceutical research company focused on developing innovative cancer treatments through small-molecule DNA-damage response (DDR) targets. Headquartered in Vancouver, Canada, the company operates as a subsidiary of NewGen Therapeutics, Inc.
Preclinical Product Pipeline
- KT-2000AI: A poly(ADP)-ribose polymerase (PARP) brain penetrant therapy for cancer.
- KT-3000: A bi-functional small-molecule drug candidate.
- KT-3283 Series: Targets PARP-resistant adult and childhood cancers.
- KT-4000: A DNA-damaging DDR inhibitor.
Research Collaborations
The company has partnered with Variational AI Inc. to identify and develop novel small-molecule therapies against DDR targets for cancer treatment.
Formerly known as Vincero Capital Corp., Rakovina Therapeutics Inc. is dedicated to advancing next-generation oncology treatments.
Frequently Asked Questions
-
What is Rakovina Therapeutics's (TSXV-RKV) current market cap?As of 06/23/2025, Rakovina Therapeutics (including the parent company, if applicable) has an estimated market capitalization of $9.18 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Rakovina Therapeutics (TSXV-RKV) rank globally by market cap?Rakovina Therapeutics global market capitalization ranking is approximately 40534 as of 06/23/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.